Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab

INTRODUCTION: Sustained improvement of high degree in clinical outcomes have been demonstrated in phase 3 trials with secukinumab in both psoriatic arthritis (PsA) and ankylosing spondylitis (AS). The objective of the SERENA study was to evaluate the effectiveness, retention rates, and safety of sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Kiltz, Uta, Sfikakis, Petros P., Gaffney, Karl, Bounas, Andreas, Gullick, Nicola, Lespessailles, Eric, Brandt-Juergens, Jan, Rashkov, Rasho, Schulz, Barbara, Pournara, Effie, Jagiello, Piotr
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174439/
https://www.ncbi.nlm.nih.gov/pubmed/35674938
http://dx.doi.org/10.1007/s40744-022-00460-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9174439/
https://www.ncbi.nlm.nih.gov/pubmed/35674938
http://dx.doi.org/10.1007/s40744-022-00460-x

Ejemplares similares